Today: 7 February 2026
Subscribe
Browse Category

Biotech News 12 January 2026 - 31 January 2026

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
··········
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio shares fell 1.6% to $6.35 after a filing showed looser conversion terms on a $505 million note held by an affiliate of executive chairman Patrick Soon-Shiong. The amendment allows partial conversions into stock, raising dilution concerns. About 16.8 million shares traded as the stock ranged from $6.28 to $6.92. New glioblastoma data will be presented Jan. 31.
26 January 2026
·····
Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics shares rose 6.5% to $22.51 in early premarket trading Monday, following a 9.65% after-hours surge Friday ahead of new Elevidys trial data. Investors await three-year results from the Phase 3 EMBARK study in Duchenne muscular dystrophy, with safety concerns heightened after FDA restrictions and patient deaths. About 17,600 shares changed hands premarket, according to Public.com.
26 January 2026
·····
Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

Sarepta stock eyes a Monday swing as Elevidys 3-year EMBARK data gets a date

New York, Jan 24, 2026, 05:28 (EST) — Market closed. Sarepta Therapeutics Inc shares climbed in after-hours trading Friday following the announcement of a Jan. 26 update on three-year data for its Duchenne gene therapy, Elevidys. The stock had closed down 3% at $21.13 but later traded near $22.20, a roughly 5% gain. (MarketWatch) The timing couldn’t be more critical. Sarepta is working to restore confidence in Elevidys after the FDA slapped on its strongest safety warning and restricted the drug’s use to patients who can still walk. This label change followed reports of deaths from acute liver failure in
24 January 2026
·····
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

New York, January 23, 2026, 11:18 EST — Regular session underway ImmunityBio shares jumped 2.7% to $7.54 in late morning trading Friday following new data on a chemo-free treatment for recurrent glioblastoma, a tough brain cancer. The stock fluctuated between $6.97 and $7.86, with over 31 million shares changing hands. Meanwhile, the SPDR S&P Biotech ETF slipped roughly 1.1%. ImmunityBio’s rally shows no signs of slowing. The stock has surged more than threefold in just three weeks and kept climbing through the first 12 trading days of 2026, according to Bloomberg. The relentless rise has pushed some short sellers to
23 January 2026
·····
ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing

ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing

New York, Jan 22, 2026, 08:54 ET — Premarket ImmunityBio shares climbed in premarket trading Thursday following the company’s announcement that U.S. regulators have specified the requirements for a new filing to expand the use of its bladder cancer treatment. This update is crucial since it sharpens a key investor question: can ImmunityBio chase a label expansion without launching fresh trials, which would mean added time and expense? Attention remains on ANKTIVA, the company’s flagship commercial product, as small-cap biotech investors look for firmer regulatory timelines before the market opens. ImmunityBio climbed roughly 6.5% to $6.92 in pre-market trading, up
22 January 2026
·····
Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge

Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge

New York, Jan 21, 2026, 12:27 EST — Regular session Shares of Corvus Pharmaceuticals edged up 0.3% to $21.48 by 12:11 p.m. EST Wednesday, swinging between $19.05 and a peak of $23.96 during a volatile session sparked by the company’s fresh capital-raising announcement. The moves carry weight since Corvus remains a clinical-stage firm. Following a strong rally on initial eczema data, it promptly sought new funding — a move that could limit short-term gains if shares are issued at a discount. The stock is caught between two forces. Bulls are betting on the broad skin data and an upcoming larger
21 January 2026
···
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

New York, January 13, 2026, 14:47 ET — During regular trading hours Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company’s updated sales forecast alongside its new five-year strategy. Based in Cambridge, Massachusetts, the company revealed preliminary 2025 sales and 2026 guidance in a Form 8-K tied to its “Alnylam 2030” plan. It warned that these figures are unaudited and may be revised before the full results come out in February. (StreetInsider.com) The news came through as executives and investors gathered at the annual J.P. Morgan Healthcare Conference, a key week when
13 January 2026
·····
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

New York, January 13, 2026, 14:17 (EST) — Regular session Shares of Travere Therapeutics (TVTX.O) dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35. (Reuters) The delay comes during a week investors saw as crucial for the small-cap drugmaker’s regulatory path. Winning an expanded label for focal segmental glomerulosclerosis (FSGS) would unlock a fresh market, beyond the drug’s existing approval for IgA nephropathy. Traders had pegged this decision
13 January 2026
····
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

New York, Jan 12, 2026, 16:34 (EST) — After-hours Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91. The company unveiled its “Alnylam 2030” initiative, aiming for “leadership in ATTR amyloidosis” and “sustained, profitable growth.” It’s targeting total revenue compound annual growth above 25% through 2030, along with a non-GAAP operating margin near 30%. For 2026, combined net product revenue is expected between $4.9 billion and $5.3 billion, spanning AMVUTTRA, ONPATTRO, GIVLAARI,
12 January 2026
·····
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading. The message is crucial as Arcutis hits a stage where investors demand more than just rapid script growth — they want evidence it can scale without another cash drain. One marketed franchise can sustain a company, until it can’t. It also
12 January 2026
·····
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

New York, Jan 12, 2026, 14:55 EST — Regular session Shares of Summit Therapeutics Inc dropped roughly 11% to $17.46 Monday afternoon, after fluctuating between $20.30 and $16.51. The move came following the company’s announcement that it filed a U.S. biologics license application for its lung cancer drug ivonescimab. (smmttx.com) Summit’s filing marks its first attempt to introduce ivonescimab to the U.S. market, targeting a challenging segment of non-small cell lung cancer (NSCLC). This involves patients with EGFR-mutated tumors whose disease has advanced despite treatment with a newer EGFR drug. The biologics license application (BLA) is the formal FDA submission
12 January 2026
····
1 2 3 … 13

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop